Frequently bought together

Brand : ARIFY

ARIFY 10/MG 30/TAB

Sku : I-033982
Key features
Arify Tablet 10mg is a prescription tablet containing aripiprazole 10mg. It works by helping balance certain brain chemicals through partial activation of dopamine and serotonin receptors and blocking serotonin 5‑HT2A receptors. It is used for the treatment of schizophrenia, bipolar I disorder, adjunctive management of major depressive disorder, irritability associated with autistic disorder, and Tourette’s disorder. It is available as a pack of 30 tablets.
- Brand: ARIFY
- Active Ingredient: ARIPIPRAZOLE 10mg
- Strength: 10mg
- Dosage Form: Tablet
- Pack Size: 30 Tablets
- Route: Oral use
- Prescription Status: Prescription
- Therapeutic Class: Psychiatric
- Pharmacological Group: Antipsychotics
- Manufacturer: Alrai Pharmaceutical industry Co. (L.L.C)
- Country of Origin: Saudi Arabia
- SFDA Registration No.: 2104245182
- Shelf Life: 24 months
- Storage: store below 30°c
- Psych Class: Antipsychotic-Atypical
- Controlled Substance: No

Frequently bought together

Description

Specification

Indications

Approved Uses

Schizophrenia; Bipolar I disorder (acute manic/mixed episodes and maintenance); Adjunctive treatment of Major Depressive Disorder; Irritability associated with autistic disorder; Tourette’s disorder (age ranges depend on local label).

Dosage & Administration

Dosing by Condition

Schizophrenia (Adults): Initial 10-15 mg once daily; target/maintenance 10-15 mg once daily; max 30 mg/day.
Bipolar I Disorder-acute manic/mixed (Adults): Initial 15 mg once daily (monotherapy) or 10-15 mg once daily (adjunct to lithium/valproate); max 30 mg/day.
Major Depressive Disorder-adjunct (Adults): Initial 2-5 mg once daily; target 5-10 mg once daily; max 15 mg/day.
Schizophrenia (Adolescents 13-17 years): Start 2 mg/day, increase to 5 mg/day, then 10 mg/day; max 30 mg/day.
Bipolar I mania (Pediatrics 10-17 years): Start 2 mg/day, titrate to 5 mg/day then 10 mg/day; max 30 mg/day.
Irritability associated with autism (Pediatrics 6-17 years): Start 2 mg/day; recommended range 5-15 mg/day; max 15 mg/day.
Tourette’s disorder (Pediatrics 6-18 years): <50 kg: start 2 mg/day; target 5 mg/day; max 10 mg/day. ≥50 kg: start 2 mg/day; target 10 mg/day; max 20 mg/day.

How to Take

Oral tablet: swallow with water; may be taken with or without food; take once daily at the same time each day as prescribed.

Side Effects

Common Side Effects

Nausea, vomiting, constipation, headache, dizziness, akathisia, somnolence, insomnia, restlessness, tremor, blurred vision, weight gain, fatigue

Side Effect Frequency

Common (≥1%): akathisia, headache, insomnia, anxiety, nausea, vomiting, constipation, dizziness, somnolence/sedation, weight gain; less common/rare but clinically important: extrapyramidal symptoms (incl. tardive dyskinesia), neuroleptic malignant syndrome, seizures, orthostatic hypotension, QT prolongation, and impulse-control disorders

Safety & Warnings

Driving Warning

May Cause Drowsiness

Drug Interactions

Major interactions: strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine, quinidine) and strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) increase levels-dose reduction often needed; strong CYP3A4 inducers (e.g., carbamazepine, rifampin) decrease levels-dose increase may be needed; additive CNS depression with alcohol/benzodiazepines/opioids; enhanced hypotension with antihypertensives.

Alcohol Interaction

Avoid

Special Populations

Breastfeeding

Caution

Kidney Impairment

No adjustment needed.

Storage & Patient Advice

Missed Dose

Take the missed dose as soon as remembered; if it is close to the next scheduled dose, skip the missed dose and resume the regular schedule; do not double doses.

Stopping the Medicine

Do not stop abruptly unless medically necessary; taper gradually under medical supervision when discontinuing.

Overdose

Overdose: commonly somnolence/lethargy, vomiting, tremor, tachycardia; may include hypotension, agitation, seizures, and ECG changes-management is supportive (airway/ventilation, activated charcoal if appropriate, cardiac/vital-sign monitoring); no specific antidote; seek emergency care.

Pharmacology

Mechanism of Action

Partial agonist at dopamine D2 (and D3) and serotonin 5‑HT1A receptors; antagonist at serotonin 5‑HT2A receptors.

Onset of Action

Pharmacokinetics: peak concentration ~3-5 hours after a dose; clinical response: partial improvement may be seen in 1-2 weeks, with fuller antipsychotic/antidepressant augmentation effects often taking 4-6 weeks.

Excretion

Primarily fecal (~55%) and to a lesser extent urinary (~25%) excretion (mostly as metabolites; minimal unchanged drug)

Product Information

Available Dosage Forms

Aripiprazole is available (globally) as: oral tablets, orally disintegrating tablets, oral solution, short-acting IM injection (immediate-release), and long-acting IM extended-release injection (LAI).